Immunotherapy Research in Oncology Focuses on Resistance
Research into the mechanisms that promote resistance to immune checkpoint blockade therapies suggests the need for new strategies for patients with immunorefractory disease.
Related Articles
FDA’s Published CRLs Deliver Insight Into the Drug Approval Process
Dive into each of the oncology-related CRLs that were recently released by the FDA, as well as relevant subsequent FDA decisions.
Atebimetinib Plus Chemo Displays Potential Survival Benefit in First-Line Pancreatic Cancer
Atebimetinib plus gemcitabine/nab-paclitaxel produced signals of survival benefits in first-line pancreatic cancer.
First-Line Ibrutinib Plus Venetoclax Demonstrates Activity in Older Patients With MCL
Ibrutinib plus venetoclax led to complete responses and durable remissions in the first-line treatment of older patients with MCL.
First-in-Human Data Support CISH Knockout Strategy to Enhance TIL Activity, Circumvent ICI Resistance in Metastatic GI Cancers
Emil Lou, MD, PhD, FACP, discusses the potential applicability of CRISPR-Cas9–mediated CISH knockout to bolster TIL responses in drug-refractory GI tumors.
Cilta-Cel Continues to Sustain PFS and OS in Relapsed/Refractory Multiple Myeloma
Surbhi Sidana, MD, highlighted the continued efficacy of cilta-cel in patients with relapsed/refractory multiple myeloma, according to an ITT analysis.
First-Line Rucaparib Maintenance Reduces Progression Risk Across Prognostic Subgroups in HRD– High-Grade Ovarian Cancer
Rucaparib maintenance improved PFS in HRD-negative advanced ovarian cancer, irrespective of baseline prognostic factors.
First-in-Human Data Support CISH Knockout Strategy to Enhance TIL Activity, Circumvent ICI Resistance in Metastatic GI Cancers
Emil Lou, MD, PhD, FACP, discusses the potential applicability of CRISPR-Cas9–mediated CISH knockout to bolster TIL responses in drug-refractory GI tumors.
Dr Randall on Addressing Disparities in Access to Specialized Sarcoma Care
R . Lor Randall, MD, FACS, discusses disparities in global access to care for patients with sarcoma.
Relacorilant/Nab-Paclitaxel Is Associated With Survival Improvement in Platinum-Resistant Ovarian Cancer After Short Platinum-Free Interval
Relacorilant plus nab-paclitaxel improved survival in platinum-resistant ovarian cancer with a primary platinum-free interval of 1 to 6 months.
Updated Data From Phase 1 Trials Support Shifts in the Lung Cancer Treatment Paradigm
Martin E. Gutierrez, MD, discusses steps towards a continuous shift in both the NSCLC and SCLC treatment paradigms, based on trials presented at ASCO 2025.